These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24047623)

  • 1. [Patient with TDS and lower urinary tract symptoms (LUTS)].
    Romero-Otero J; García B; Jiménez Alcalde E; García Cruz E; Leibar Tamayo A; Rodríguez Antolín A
    Arch Esp Urol; 2013 Sep; 66(7):657-62. PubMed ID: 24047623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of lower urinary tract symptom/benign prostatic hyperplasia measures with international index of erectile function 5 in middle-aged policemen of Korea and the role of metabolic syndrome and testosterone in their relationship.
    Lee JH; Kwon H; Park YW
    Urology; 2013 Nov; 82(5):1008-12. PubMed ID: 24041675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone supplementation does not worsen lower urinary tract symptoms.
    Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
    J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
    Francomano D; Ilacqua A; Bruzziches R; Lenzi A; Aversa A
    Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
    Porst H; Oelke M; Goldfischer ER; Cox D; Watts S; Dey D; Viktrup L
    Urology; 2013 Sep; 82(3):667-73. PubMed ID: 23876588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Kaplan SA; Lee JY; O'Neill EA; Meehan AG; Kusek JW
    Aging Male; 2013 Dec; 16(4):169-72. PubMed ID: 24134648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone and the Prostate: Artifacts and Truths.
    DeLay KJ; Kohler TS
    Urol Clin North Am; 2016 Aug; 43(3):405-12. PubMed ID: 27476133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia.
    Park SG; Yeo JK; Cho DY; Park MG
    Aging Male; 2018 Mar; 21(1):55-59. PubMed ID: 28414251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
    Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
    J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
    Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.